| Business Summary | | Emisphere
Technologies,
Inc.
is
a
biopharmaceutical
company
offering
products
that
enable
the
oral
delivery
of
medicines
which,
for
a
variety
of
reasons,
cannot
be
offered
to
patients
in
an
oral
form.
The
Company
has
several
product
candidates
in
preclinical
and
clinical
development
across
a
broad
range
of
therapeutic
areas
including,
cardiovascular,
osteoporosis,
growth
disorders,
obesity,
diabetes,
allergies/asthma
and
infectious
diseases.
The
Company's
proprietary
oral
drug
delivery
agents
represent
a
broad-based
technology
platform.
The
Company's
carriers,
which
mimic
the
body's
transport
process,
allow
macromolecules
to
cross
membranes
and
yet
remain
therapeutically
active. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | EMIS
is
a
biopharmaceutical
company
focused
on:
the
development
of
oral
heparin
products;
the
application
of
proprietary
synthetic
chemical
compounds;
the
development
of
oral
formulations
of
selected
therapeutic
macromolecules.
For
the
comparable
six
months
ended
6/30/01,
revenues
rose
17%
to
$2.9
million.
Net
loss
increased
69%
to
$19.8
million.
Results
reflect
revenues
from
the
collaboration
with
Eli
Lilly,
offset
by
higher
salary
and
product
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Michael Goldberg, M.D., 41 Chairman,
CEO | $402K | $2.0M | Robert Baughman, Jr., Ph.D., 51 Sr.
VP of Devel. | 210K | 71K | Lewis Bender, 41 Sr.
VP of Bus. Devel. and Manufacturing | 214K | 58K | Shepard Goldberg, 45 VP
of Operations | -- | -- | Charles Abdalian, Jr., 50 VP,
CFO and Sec. | 181K | 42K | Dollar
amounts are as of 31-July-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|